keyword
MENU ▼
Read by QxMD icon Read
search

ovarian cancer early diagnosis

keyword
https://www.readbyqxmd.com/read/28653032/paraneoplastic-antigens-as-biomarkers-for-early-diagnosis-of-ovarian-cancer
#1
REVIEW
Madhumita Chatterjee, Laura C Hurley, Michael A Tainsky
Paraneoplastic syndromes are a group of rare disorders that can be triggered by an abnormal immune response to proteins from tumors of the lung, ovary, lymphatics, or breast. Paraneoplastic clinical syndromes affect < 1% of patients with cancer; however, the frequency of subclinical levels of paraneoplastic autoantibodies in asymptomatic patients with cancer is unknown. Numerous studies have reported that ovarian cancer patients show signs of paraneoplastic neurological syndromes (PNSs) before or after their cancers are diagnosed...
August 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28652099/influence-of-adjuvant-chemotherapy-on-anti-m%C3%A3-llerian-hormone-in-women-below-35-years-treated-for-early-breast-cancer
#2
Anne Perdrix, Mathilde Saint-Ghislain, Marie Degremont, Marion David, Zena Khaznadar, Agnès Loeb, Marianne Leheurteur, Frédéric Di Fiore, Florian Clatot
The impact of chemotherapy on fertility appears to be of essential importance for the youngest cancer survivors. The aim of this study was to assess plasma anti-Mullërian hormone (AMH) evolution, using an automated sensitive AMH immunoassay in women younger than 35 years old before and after treatment with adjuvant chemotherapy for early breast cancer. We selected 54 women aged less than 35 years old, at the time of breast cancer diagnosis, who received chemotherapy between 2008 and 2014, and with plasma samples collected from the diagnosis, to 1 year, 3 years and 5 years post-diagnosis...
June 15, 2017: Reproductive Biomedicine Online
https://www.readbyqxmd.com/read/28651933/nuclear-%C3%AE-catenin-positivity-as-a-predictive-marker-of-long-term-survival-in-advanced-epithelial-ovarian-cancer
#3
Bence Nagy, László Tóth, Péter Molnár, Gábor Méhes, László Thurzó, Róbert Póka, Zoltán Hernádi
BACKGROUND: Classical features as histomorphology, grade, FIGO stage, and residual tumour mass have strong prognostic value in advanced epithelial ovarian carcinomas (AEOC). Most AEOCs are associated with early recurrence and poor overall survival (OS). Despite of early recurrence, general poor outcome, both high grade tumours or tumours with advanced FIGO stage at the time of diagnosis, in some of such cases, long-term survival (LTS) has been recorded . The aim of this study was to compare the utility of "classical" prognostic factors to molecular factors such as β-catenin- E-cadherin-, mutated TP53-, and MiB-1 (Ki-67) labelling index determination in predicting long-term survival...
June 10, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28640083/clinical-significance-of-plasma-d-dimer-in-ovarian-cancer-a-meta-analysis
#4
Jiacong Wu, Ziyi Fu, Guangquan Liu, Pengfei Xu, Juan Xu, Xuemei Jia
BACKGROUND: D-dimer has been widely used for the diagnosis and prognosis of ovarian cancer, but there is still controversy on its prediction value of ovarian cancer. OBJECTIVES: To explore the clinical significance of plasma D-dimer level on ovarian cancer systematically. METHODS: Using PubMed, Cochrane Library, and Web of Science libraries, all the relevant studies for the diagnostic and prognostic value of plasma D-dimer for ovarian cancer and the relationship between elevated D-dimer level and venous thromboembolism (VTE) risk of ovarian cancer were searched till May 30, 2016...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28637689/elevation-of-tp53-autoantibody-prior-to-ca125-in-preclinical-invasive-epithelial-ovarian-cancer
#5
Wei-Lei Yang, Aleksandra Gentry-Maharaj, Archana R Simmons, Andy Ryan, Evangelia O Fourkala, Zhen Lu, Keith A Baggerly, Yang Zhao, Karen Lu, David D L Bowtell, Ian Jacobs, Steven J Skates, Wei-Wu He, Usha Menon, Robert C Bast
Purpose: The TP53 tumor suppressor gene is mutated in >95% of high grade serous ovarian cancers. Detecting an autologous antibody response to TP53 might improve early detection. <p>Experimental design: An immunoassay was developed to measure TP53 autoantibody in sera from 378 cases of invasive epithelial ovarian cancer and in 944 age-matched healthy controls from the United States, Australia and the United Kingdom. Serial preclinical samples from cases and controls were also assayed from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)...
June 21, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28636295/-screening-of-ovarian-cancer-not-for-tomorrow
#6
Aurélie Vuilleumier, Intidhar Labidi-Galy
As the worldwide incidence of cancer continuously rises, one of the measures to reduce mortality is early diagnosis while the disease is still curable. Colonoscopy screening and PAP-smears are worthwhile examples illustrating the impact of early diagnosis on mortality. Ovarian cancer is the first cause of mortality by gynecological cancers in Switzerland (incidence of 600 new cases / year), mostly diagnosed at advanced stages with a poor prognosis. Could surveillance measures improve survival ? Three large-scale randomized control trials failed to show mortality reduction from ovarian cancer with the methods currently available...
May 17, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28632866/risks-of-breast-ovarian-and-contralateral-breast-cancer-for-brca1-and-brca2-mutation-carriers
#7
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu, David E Goldgar, Mary Beth Terry, Matti A Rookus, Douglas F Easton, Antonis C Antoniou, Lesley McGuffog, D Gareth Evans, Daniel Barrowdale, Debra Frost, Julian Adlard, Kai-Ren Ong, Louise Izatt, Marc Tischkowitz, Ros Eeles, Rosemarie Davidson, Shirley Hodgson, Steve Ellis, Catherine Nogues, Christine Lasset, Dominique Stoppa-Lyonnet, Jean-Pierre Fricker, Laurence Faivre, Pascaline Berthet, Maartje J Hooning, Lizet E van der Kolk, Carolien M Kets, Muriel A Adank, Esther M John, Wendy K Chung, Irene L Andrulis, Melissa Southey, Mary B Daly, Saundra S Buys, Ana Osorio, Christoph Engel, Karin Kast, Rita K Schmutzler, Trinidad Caldes, Anna Jakubowska, Jacques Simard, Michael L Friedlander, Sue-Anne McLachlan, Eva Machackova, Lenka Foretova, Yen Y Tan, Christian F Singer, Edith Olah, Anne-Marie Gerdes, Brita Arver, Håkan Olsson
Importance: The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospective cancer risk estimates. Objectives: To estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location. Design, Setting, and Participants: Prospective cohort study of 6036 BRCA1 and 3820 BRCA2 female carriers (5046 unaffected and 4810 with breast or ovarian cancer or both at baseline) recruited in 1997-2011 through the International BRCA1/2 Carrier Cohort Study, the Breast Cancer Family Registry and the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, with ascertainment through family clinics (94%) and population-based studies (6%)...
June 20, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28631073/compartment-syndrome-after-gynecologic-laparoscopy-systematic-review-of-the-literature-and-establishment-of-normal-values-for-postoperative-serum-creatine-kinase-and-myoglobin-levels
#8
Katrin Hefler-Frischmuth, Judith Lafleur, Gudrun Brunnmayr-Petkin, Franz Roithmeier, Verena Unterrichter, Lukas Hefler, Clemens Tempfer
PURPOSE: To evaluate published evidence in the literature on compartment syndrome (CS) in association with gynecologic surgery and to establish postoperative normal values for serum creatine kinase (CK) and myoglobin. METHODS: The present study consists of a case report of a patient with CS, a systematic review including 37 studies and 86 patients with CS, and a retrospective cohort study of 300 patients undergoing various types of laparoscopy for benign or malignant diseases in order to establish postoperative normal values...
June 19, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28626404/case-of-ovarian-cancer-in-a-woman-with-undiagnosed-graves-disease-a-case-report-and-review-of-the-literature
#9
Timothy M Markman, Maurie Markman, Bennett W Clark
Epithelial ovarian cancer (OC) is a leading cause of death among females in the United States, due in part to challenges of diagnosis in the early stages of the disease. While efforts are underway to develop a high-quality screening test, it is equally important to consider whether high-risk populations are appropriate to screen. One such population may be females with hyperthyroidism, as epidemiologic studies have shown an association between this condition and OC. In this report, we present a case of a female with OC and Graves' disease to highlight the potential significance of this association...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28615616/early-stage-mucinous-ovarian-adenocarcinoma-with-extensive-clotting-in-a-previously-healthy-young-female-patient-an-uncommon-presentation-of-a-relatively-uncommon-disease
#10
Suchin R Khanna, Brave Nguyen, Mahmoud Charif
BACKGROUND Mucinous ovarian adenocarcinoma is one of the less common epithelial cancers of the ovaries, and typically does not occur in younger women. Nearly all mucinous ovarian adenocarcinomas present with early-stage disease without significant sequelae of cancer, such as clotting. Anchoring bias is a common problem in medicine that has been shown to significantly affect physician decision-making. CASE REPORT We present the case of a 24-year-old healthy female Chinese immigrant with no significant past medical history, who presented with a subacute history of nonproductive cough and shortness of breath with exertion...
June 15, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28611536/germline-mutations-in-triple-negative-breast-cancer
#11
REVIEW
Eric Hahnen, Jan Hauke, Christoph Engel, Guido Neidhardt, Kerstin Rhiem, Rita K Schmutzler
Triple-negative breast cancer (TNBC) is associated with a poor prognosis and defines a subgroup of patients who do not benefit from endocrine or anti-HER2 therapy. Rather than being a biological entity, TNBC represents a heterogeneous disease, and further subtyping is necessary to establish targeted therapies. Germline mutational status may serve as a robust biomarker predicting therapy response, especially with respect to compounds challenging the DNA repair machinery. Patients with TNBC usually show an early onset of the disease, as well as a positive family history of breast and/or ovarian cancer in more than one third of all cases, which suggests that TNBC is closely associated with a hereditary disease cause...
March 2017: Breast Care
https://www.readbyqxmd.com/read/28599499/comparative-secretome-of-ovarian-serous-carcinoma-gelsolin-in-the-spotlight
#12
Sandra Pierredon, Pascale Ribaux, Jean-Christophe Tille, Patrick Petignat, Marie Cohen
Ovarian cancer is one of the most common types of reproductive cancer, and has the highest mortality rate amongst gynecological cancer subtypes. The majority of ovarian cancers are diagnosed at an advanced stage, resulting in a five-year survival rate of ~30%. Early diagnosis of ovarian cancer has improved the five-year survival rate to ≥90%, thus the current imperative requirement is to identify biomarkers that would allow the early detection, diagnosis and monitoring of the progression of the disease, or of novel targets for therapy...
June 2017: Oncology Letters
https://www.readbyqxmd.com/read/28578437/clinical-value-of-combining-transvaginal-contrast-enhanced-ultrasonography-with-serum-human-epididymisprotein-4-and-the-resistance-index-for-early-stage-epithelial-ovarian-cancer
#13
Wu Meng, Wang Ying, Zheng Qichao, Li Ping, Tang Jie
To increase accuracy of the detection and differential diagnosis of the early epithelial ovarian cancer (EOC) with transvaginal contrast-enhanced ultrasonography (TVCEUS) combining serum human epididymisprotein 4 (HE4), and resistance index (RI). Methods: This retrospectively case-control study of 230 patients with ovarian tumors were reviewed at the Department of Gynecology and Obstetrics, Zhongnan Hospital, Wuhan University, Wuhan, China between June 2008 and September 2015. Before the operation of 110 cases with EOC (Group A) and 120 cases of patients with benign ovarian tumor (Group B), we observe and calculate both Groups' tumor vascular contrast-enhanced ultrasonography morphology scores (U), time-intensity curve (TIC) of contrast-enhanced ultrasonography, HE4, and RI...
June 2017: Saudi Medical Journal
https://www.readbyqxmd.com/read/28574444/validation-of-the-performance-of-international-ovarian-tumor-analysis-iota-methods-in-the-diagnosis-of-early-stage-ovarian-cancer-in-a-non-screening-population
#14
Wouter Froyman, Laure Wynants, Chiara Landolfo, Tom Bourne, Lil Valentin, Antonia Testa, Povilas Sladkevicius, Dorella Franchi, Daniela Fischerova, Luca Savelli, Ben Van Calster, Dirk Timmerman
BACKGROUND: The aim of this study was to assess and compare the performance of different ultrasound-based International Ovarian Tumor Analysis (IOTA) strategies and subjective assessment for the diagnosis of early stage ovarian malignancy. METHODS: This is a secondary analysis of a prospective multicenter cross-sectional diagnostic accuracy study that included 1653 patients recruited at 18 centers from 2009 to 2012. All patients underwent standardized transvaginal ultrasonography by experienced ultrasound investigators...
June 2, 2017: Diagnostics
https://www.readbyqxmd.com/read/28562469/gynecological-cancer-as-a-second-malignancy-in-patients-with-breast-cancer
#15
Budhi Singh Yadav, Suresh C Sharma, Firuza D Patel, Bhavana Rai, Sushmita Ghoshal
PURPOSE: The aim of this study was to determine the incidence and risk factors for gynecological cancer as second malignancy (SM) after treatment of breast cancer (BC). METHODS AND MATERIALS: Between January 1985 and December 2007, a total of 2756 patients with BC were analyzed for gynecological cancers as an SM. Analysis was carried out for patient-, disease-, and treatment-related characteristics. The Cox proportional hazards regression model was used to estimate the relative risk of gynecologic malignancies...
May 29, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28561672/pancreatic-adenocarcinoma-improving-prevention-and-survivorship
#16
Davendra P S Sohal, Field F Willingham, Massimo Falconi, Kara L Raphael, Stefano Crippa
Pancreatic cancer is a growing problem in oncology, given slowly rising incidence and continued suboptimal outcomes. A concerted effort to reverse this tide will require prevention, early diagnosis, and improved systemic therapy for curable disease. We focus on these aspects in detail in this study. Hereditary pancreatic cancer is an underappreciated area. With the growing use of genomics (both somatic and germline) in cancer care, there is increasing recognition of hereditary pancreatic cancer cases: around 10% of all pancreatic cancer may be related to familial syndromes, such as familial atypical multiple mole and melanoma (FAMMM) syndrome, hereditary breast and ovarian cancer, Lynch syndrome, and Peutz-Jeghers syndrome...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28559958/hereditary-and-non-hereditary-branches-of-family-eligible-for-brca-test-cancers-in-other-sites
#17
M Digennaro, D Sambiasi, S Tommasi, B Pilato, S Diotaiuti, A Kardhashi, G Trojano, A Tufaro, A V Paradiso
BACKGROUND: The analysis of relationships of BRCA alterations with cancer at sites other than breast/ovary may provide innovative information concerning BRCA pathogenic role and support additional clinical decisions. Aim of this study is to compare presence of cancers in other sites in members of hereditary (H) and not-hereditary (nH) branches of families of patients eligible to BRCA test. METHODS: We retrospectively analyzed the incidence of cancer in other sites in members of 136 families eligible for hereditary breast/ovarian cancer genetic counseling at Centro Studi Tumori Eredo-familiari of our Institute; we compared the frequency of other cancer types in 1156 members of the H-branch with respect to 1062 members of nH-Branch...
2017: Hereditary Cancer in Clinical Practice
https://www.readbyqxmd.com/read/28549791/micrornas-in-gynecological-cancers-small-molecules-with-big-implications
#18
Sanjeev K Srivastava, Aamir Ahmad, Haseeb Zubair, Orlandric Miree, Seema Singh, Rodney P Rocconi, Jennifer Scalici, Ajay P Singh
Gynecological cancers (GCs) are often diagnosed at advanced stages, limiting the efficacy of available therapeutic options. Thus, there remains an urgent and unmet need for innovative research for the efficient clinical management of GC patients. Research over past several years has revealed the enormous promise of miRNAs. These small non-coding RNAs can aid in the diagnosis, prognosis and therapy of all major GCs, viz., ovarian cancers, cervical cancers and endometrial cancers. Mechanistic details of the miRNAs-mediated regulation of multiple biological functions are under constant investigation, and a number of miRNAs are now believed to influence growth, proliferation, invasion, metastasis, chemoresistance and the relapse of different GCs...
May 24, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28548905/brca-associated-cancers-role-of-imaging-in-screening-diagnosis-and-management
#19
Michelle V Lee, Venkata S Katabathina, Michyla L Bowerson, Marina I Mityul, Anup S Shetty, Khaled M Elsayes, Aparna Balachandran, Priya R Bhosale, Ann E McCullough, Christine O Menias
Harmful mutations of the BRCA tumor suppressor genes result in a greater lifetime risk for malignancy-breast and ovarian cancers in particular. An increased risk for male breast, fallopian tube, primary peritoneal, pancreatic, prostate, and colon cancers also has been reported. The BRCA gene is inherited in an autosomal dominant pattern and tends to be highly penetrant; thus, there is an increased incidence of these cancers in affected families. Compared with sporadic tumors, BRCA-associated malignancies have unique manifestations, clinical features, and pathologic profiles...
May 26, 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28539285/-diagnostic-value-of-ca125-he4-and-copenhagen-index-in-differentiating-benign-from-malignant-epithelial-ovarian-tumors
#20
Shi-Peng Gong, Yong-Ning Chen, Ya-di Zhang, Wei Yao, Li Chen, Shi-San Liu, Huan Wu
OBJECTIVE: To analyze diagnostic value of Copenhagen Index based on pretreatment serum CA125, HE4 and age in differentiating benign and malignant epithelial ovarian tumors. METHODS: The clinical data were analyzed for 208 consecutive patients with epithelial ovarian tumors (including 100 with malignant and 108 with benign tumors) treated in our department between September, 2014 and September, 2016. The receiver-operating characteristic curve was drawn based on the golden standard of pathological diagnosis for calculation of the diagnostic sensitivity and specificity of CA125, HE4 and the Copenhagen Index...
May 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
keyword
keyword
86585
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"